Aspirin and NSAIDs; Benefits and harms for the gut

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 2, 2012, Pages 197-206

  Thiagarajan, Prarthana ^a   Jankowski, Janusz A ^a,b,c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chemoprevention; Colorectal cancer; Oesophageal cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CORTICOSTEROID; DA 9601; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MELOXICAM; METHOTREXATE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE; SULINDAC; UNCLASSIFIED DRUG; VALPROIC ACID; VENLAFAXINE; WARFARIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ANGIONEUROTIC EDEMA; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BARRETT ESOPHAGUS; BRAIN HEMORRHAGE; BRONCHOSPASM; CANCER INCIDENCE; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; EPIGASTRIC PAIN; ERADICATION THERAPY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART PROTECTION; HELICOBACTER INFECTION; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MORTALITY; NAUSEA; OSTEOARTHRITIS; OXIDATIVE PHOSPHORYLATION; PEPTIC ULCER; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; REYE SYNDROME; RHINOSINUSITIS; RISK BENEFIT ANALYSIS; STOMACH DISEASE; STOMACH ULCER; TREATMENT RESPONSE; URTICARIA;

ADENOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BARRETT ESOPHAGUS; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL HEMORRHAGE; HUMANS;

EID: 84860259045     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.01.007     Document Type: Article

References (47)

1. http://info.cancerresearchuk.org/cancerstats/world/colorectal-cancer- world/ [accessed 30.11.11]
2. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide 2010 International Agency for Research on Cancer IARC CancerBase No. 10 Internet Lyon, France Available from: http://globocan.iarc.fr www.cancerresearchuk.org [accessed 30.11.11]
3. R.S. Holmes, and T.L. Vaughan Epidemiology and pathogenesis of esophageal cancer Semin Radiat Oncol 17 2007 2 9
4. E. Bollschweiler, E. Wolfgarten, C. Gutschow, and A.H. Hölscher Demographic variations in the rising incidence of esophageal adenocarcinoma in white males Cancer 92 3 2001 549 555
5. S.J. Crane, G.R. Locke 3rd, W.S. Harmsen, A.R. Zinsmeister, Y. Romero, and N.J. Talley Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study Mayo Clin Proc 83 10 2008 Oct 1087 1094
6. V. Fuster, and J. Sweeny Contemporary reviews in cardiovascular medicine Circulation 123 7 2011 Feb 22 768 778
7. H. Jankowska, P. Hooper, and J.A. Jankowski Aspirin chemoprevention of gastrointestinal cancer in the next decade. A review of the evidence Pol Arch Med Wewn 120 10 2010 Oct 407 412
8. A. Gonzalez-Perez, L.A. Garcia Rodriguez, and R. Lopez-Ridaura Effects of nonsteroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis BMC Cancer 3 2003 28
9. T.L. Vaughan, L.M. Dong, and P.L. Blount Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study Lancet Oncol 6 2005 945 952
10. D.C. Farrow, T.L. Vaughan, and P.D. Hansten Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 7 1998 97 102
11. T.K. Asano, and R.S. McLeod Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas Cochrane Database Syst Rev 2 2004 CD004079
12. M.V. Grau, R.S. Sandler, G. McKeown-Eyssen, R.S. Bresalier, R.W. Haile, and E.L. Barry Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study J Natl Cancer Inst 101 4 2009 Feb 18 267 276
13. E. Flossmann, and P.M. Rothwell British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies Lancet 369 9573 2007 May 12 1603 1613
14. K. Cooper, H. Squires, C. Carroll, D. Papaioannou, A. Booth, and R.F. Logan Chemoprevention of colorectal cancer: systematic review and economic evaluation Health Technol Assess 14 32 2010 Jun 1 206
15. J.A. Jankowski, and P.A. Hooper Chemoprevention in Barrett's esophagus: a pill a day? Gastrointest Endosc Clin N Am. 21 1 2011 Jan 155 170
16. A. Lanas, P. Wu, J. Medin, and E.J. Mills Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis Clin Gastroenterol Hepatol 9 9 2011 Sep 762 768.e6
17. E.S. Huang, L.L. Strate, W.W. Ho, S.S. Lee, and A.T. Chan Long-term use of aspirin and the risk of gastrointestinal bleeding Am J Med 124 5 2011 May 426 433
18. D.H. Solomon, J. Avorn, T. Stürmer, R.J. Glynn, H. Mogun, and S. Schneeweiss Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk Arthritis Rheum 54 5 2006 May 1378 1389
19. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, and C. Patrono Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomized trials BMJ 332 2006 1302 1308
20. J. He, P.K. Whelton, and B. Vu Aspirin and risk of hemorrhagic stroke: a metaanalysis of randomized control trials JAMA 280 1998 1930 1935
21. P. Saloheimo, M. Ahonen, S. Juvela, J. Pyhtinen, E.R. Savolainen, and M. Hillbom Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death Stroke 37 1 2006 Jan 129 133
22. V.L. Serebruany, A.I. Malinin, R.M. Eisert, and D.C. Sane Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials Am J Hematol 75 2004 40 47
23. de Jong PT, Chakravarthy U, Rahu M, Seland J, Soubrane G, Topouzis F, et al. Associations between aspirin use and aging macula disorder the European Eye study. Ophthalmology; 2011 Sep 13. Epub ahead of print.
24. W.G. Christen, R.J. Glynn, E.Y. Chew, and J.E. Buring Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women Ophthalmology 116 12 2009 Dec 2386 2392
25. C. Jenkins, J. Costello, and L. Hodge Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice BMJ 328 2004 434
26. M.L. Fajt, and A.A. Petrov Outpatient aspirin desensitization for patients with aspirin hypersensitivity and cardiac disease Crit Pathw Cardiol 10 1 2011 Mar 17 21
27. A. Szczeklik, and M. Sanak The broken balance in aspirin hypersensitivity Eur J Pharmacol 533 1-3 2006 Mar 8 145 155
28. R.A. Settipane, H.P. Constantine, and G.A. Settipane Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review Allergy 35 1980 149 154
29. C.E. Grattan Aspirin sensitivity and urticaria Clin Exp Dermatol 28 2003 123 127
30. J.H. Choi, S.H. Kim, C.H. Suh, D.H. Nahm, and H.S. Park Polymorphisms of high-affinity IgE receptor and histamine-related genes in patients with ASA-induced urticaria/angioedema J Korean Med Sci 20 3 2005 Jun 367 372
31. M. Moriya, M. Aihara, R. Hirota, Y. Hirata, N. Ikinaga, and N. Takamura Analysis of 76 patients with urticaria and angioedema induced by non-steroidal anti-inflammatory drugs (NSAIDs) in Japan Arerugi 60 6 2011 Jun 699 707
32. J.A. Gosalakkal, and V. Kamoji Reye syndrome and reye-like syndrome Pediatr Neurol 39 3 2008 Sep 198 200
33. R. Segal, E. Lubart, A. Leibovitz, A. Iaina, and D. Caspi Renal effects of low dose aspirin in elderly patients Isr Med Assoc J 8 10 2006 Oct 679 682
34. N. O'Connor, P.I. Dargan, and A.L. Jones Hepatocellular damage from non-steroidal anti-inflammatory drugs QJM 96 11 2003 Nov 787 791
35. G.P. Aithal, and C.P. Day Nonsteroidal anti-inflammatory drug-induced hepatotoxicity Clin Liver Dis 11 3 2007 Aug 563 575 vi-vii
36. Y. Masubuchi, S. Yamada, and T. Horie Possible mechanisms of hepatocyte injury induced by diphenylamine and its structurally related NSAIDS J Pharmacol Exp Ther 292 2000 982 987
37. N. Yeomans, A. Lanas, J. Labenz, S.V. van Zanten, C. van Rensburg, and I. Rácz Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin Am J Gastroenterol 103 10 2008 Oct 2465 2473
38. M. Vergara, M. Catalán, J.P. Gisbert, and X. Calvet Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users Aliment Pharmacol Ther 21 12 2005 Jun 15 1411 1418
39. H.T. de Leest, K.S. Steen, W.F. Lems, J.W. Bijlsma, M.A. van de Laar, and A.M. Huisman Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial Helicobacter 12 5 2007 Oct 477 485
40. N.M. Agrawal, J. Caldwell, A.J. Kivitz, A.L. Weaver, T.S. Bocanegra, and J. Ball Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers Clin Ther 21 1999 659 674
41. K.N. Lee, O.Y. Lee, M.G. Choi, S.R. Choi, D.H. Lee, and Y.C. Lee Prevention of NSAID-associated gastroduodenal injury in healthy volunteers-a randomized, double-blind, multicenter study comparing DA-9601 with misoprostol J Korean Med Sci. 26 8 2011 Aug 1074 1080
42. P.M. Rothwell, M. Wilson, C.E. Elwin, B. Norrving, A. Algra, and C.P. Warlow Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 9754 2010 Nov 20 1741 1750
43. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet; 2011 Oct 27. Epub ahead of print.
44. A.W. DuPont, M.R. Arguedas, and C.M. Wilcox Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis Aliment Pharmacol Ther 26 3 2007 Aug 1 431 441
45. H. Squires, P. Tappenden, K. Cooper, C. Carroll, R. Logan, and D. Hind Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Clin Ther 33 9 2011 Sep 1289 1305
46. C. Hur, D.E. Broughton, and E. Ozane Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus Am J Gastroenterol 103 2008 2432 2442
47. D. Das, A.P. Chilton, and J.A. Jankowski Chemoprevention of esophageal cancer and the AspECT trial Recent Results Cancer Res 181 2009 161 168